nach oben

Erschienen in:

13.01.2020 | Original Article

The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer

verfasst von: Risa Goto, Yuko Hirota, Tomoyuki Aruga, Shinichiro Horiguchi, Sakiko Miura, Seigo Nakamura, Masafumi Takimoto

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In breast cancer, FoxP3-positive tumor-infiltrating lymphocytes (FoxP3+ TILs) vary depending on lymph node status, histological grade, and subtype. All these studies have compared the numbers of FoxP3+ TILs among different hosts, but recruitment of FoxP3+ TILs might depend on each individual’s immune environment and each tumor’s biological characteristics. In the present study, FoxP3+ TIL numbers were investigated in patients with synchronous bilateral breast cancer (SBBC) to determine the factors that affect FoxP3+ TIL recruitment in the same anti-tumor immune environment.

Methods

Patients diagnosed with SBBC who underwent curative surgery at two institutions were enrolled in this study. Patients who underwent primary systemic therapy or who were diagnosed with ductal carcinoma in situ or who had distant metastases at diagnosis were excluded. The average numbers of Foxp3+ TILs were determined from the scores of five high-power microscopic fields (HPF). The associations between Foxp3+ TIL numbers and the clinicopathological features of bilateral breasts in a single individual were examined.

Results

Nuclear grade (NG) (p = 0.007) and subtype (p = 0.03), but not size (p = 0.18) and axillary lymph node (p = 0.23) were significantly associated with increase of FoxP3 + TIL numbers by univariate analysis. Further, only NG was a statistically significant clinicopathological factor for change in the number of FoxP3+ TILs by multivariate analysis (p = 0.046)

Conclusions

There was no relationship between FoxP3+ TIL numbers and cancer progression as reflected in tumor size and axillary lymph node in patients with SBBC. Aggressive biological factors, especially high NG, were significantly related to enhanced recruitment of FoxP3+ TILs.

Nur mit Berechtigung zugänglich

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMed

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.CrossRefPubMedPubMedCentral

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34.CrossRefPubMed

Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010; 11(1):7–13

Levings MK, Sangregorio R, Human RMG. cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded invitro without loss of function. J Exp Med. 2001;193(11):1295–302.CrossRefPubMedPubMedCentral

Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98(9):2736–44.CrossRefPubMed

Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2(6):389–400.CrossRefPubMed

Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol. 2003;3(3):189–98.CrossRefPubMed

Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol. 2004;4(11):889–99.CrossRefPubMed

10.

Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Sci (N Y). 2003;299(5609):1057–61.CrossRef

11.

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.CrossRefPubMed

12.

deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18(11):3022–9.CrossRefPubMed

13.

Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345–52.CrossRefPubMed

14.

Jiang D, Gao Z, Cai Z, Wang M, He J. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15:727.CrossRefPubMedPubMedCentral

15.

Nichol AM, Yerushalmi R, Tyldesley S, Lesperance M, Bajdik CD, Speers C, et al. A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol. 2011;29(36):4763–8.CrossRefPubMed

16.

Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007;105(3):347–57.CrossRefPubMed

17.

Kurebayashi J, Miyosi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22(3):235–44.

18.

Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer, the 17 Kanehara & Co. Ltd, Tokyo; 2012.

19.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMed

20.

Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Kitagawa D, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009;22:273–8.PubMed

21.

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.CrossRef

22.

Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9(9):XC05–8.

23.

Renz DM, Böttcher J, Baltzer PA, Dietzel M, Vag T, Gajda M, et al. The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer. Breast Cancer Res Treat. 2010;120(2):449–59.CrossRefPubMed

24.

Baker B, Morcos B, Daoud F, Sughayer M, Shabani H, Salameh H, et al. Histo-biological comparative analysis of bilateral breast cancer. Med Oncol. 2013;30(4):711.CrossRefPubMed

25.

Liu F, Lang R, Zhao J, Zhang X, Fan Y, et al. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–55.CrossRefPubMed

26.

Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli G. Human FOXP3 and cancer. Oncogene. 2010;29:4121–9.CrossRefPubMed

Titel: The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer
verfasst von: Risa Goto
Yuko Hirota
Tomoyuki Aruga
Shinichiro Horiguchi
Sakiko Miura
Seigo Nakamura
Masafumi Takimoto
Publikationsdatum: 13.01.2020
Verlag: Springer Japan
Erschienen in: Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-020-01049-4

Springer Medizin

The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer